Biomedical Bonding AB is a Swedish Medtech company that develops new orthopaedic solutions and novel surgical methodologies for bone fracture fixation and restoration. BMB´s aims to introduce a paradigm shift in bone fixation and restoration in order to minimise recovery time, post-surgical complications and patients’ discomfort. The core technology is based on an advanced adhesive composite that can replace or enhance current metal and polymer-based implants and fillers in bone fracture/restoration treatments. BMB´s fracture fixation technology platform is based on more than 10 years of academic research conducted at Royal Institute of Technology (KTH) with support from Research Institutes of Sweden (RISE), Karolinska University Hospital (KUH) and Stockholm South General Hospital (SSGH). BMB has concentrated its Intellectual Property Rights (IPR) in internal know-how and three international patent applications (PCT).
Several large bone fracture segments have been identified as the first clinical markets to penetrate, such as maxillofacial, hand, distal radius, ankle fractures and craniotomy. These alone account for at least 2.7 million cases yearly in the western world with a population of 1.1 billion inhabitants. TAM for bone fixation and restoration is worth over €5.9B with a CAGR of 9% until 2020.
This is reflected by a growing and elderly population that is the overall market driver. Only for hand fractures in EU and US (1.1 B inh.) there are annually about 330 000 fracture cases that requires Open Reduction Internal Fixation (ORIF). For ankle and distal radius fractures the corresponding numbers are 1.1 M and 440 000 respectively. A few large Medtech companies dominate the market and there are currently no options other than metal plates and screws for ORIF. While multiple products and clinical applications are envisioned for rapid expansion, BMB has the ambition to initially go-to-market within 3 years based on two innovative adhesive products, AdhFix and DendroPrime. BMB now seeks investors to join BMB in its journey to commercialise a unique adhesive technology that will modernise surgical treatments of fractures and bone restorations.
BioMedical Bonding are presenting to investors at the 2nd LSX Nordic Congress, Stockholm, 28-29 August.
Take a look at their investor prospectus here.